

Ref: SPL/CORP-SEC/2026-27/BSE/462

Dated:11.07.2026

To,
**Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001**

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting held on 11TH July 2026 with Scrip Code 524703.

Ref: Regulations 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations. 2015

A Meeting of the Board of Directors of the Company duly convened on Saturday, 11th July 2026 at 04:00 p.m. and concluded at 05:20 p.m. discussed the following business: -

1. TOOK NOTE OF THE DEMISE OF SHRI UMESH B. SANDU, MANAGING DIRECTOR (DIN: 01132141)

The Board of Directors took note, with profound grief and deep sorrow, of the demise of **Shri Umesh B. Sandu (DIN: 01132141)**, Managing Director of the Company, who passed away on 19th June, 2026.

The Board placed on record its sincere appreciation for his invaluable guidance, dedicated leadership, and significant contribution towards the growth and development of the Company during his tenure. The Directors expressed their heartfelt condolences to the bereaved family and prayed for the eternal peace of the departed soul.

2. APPOINTMENT OF DR. NEETI MADAN KAPRE (DIN: 06801264) AS AN ADDITIONAL NON-EXECUTIVE INDEPENDENT DIRECTOR OF THE COMPANY.

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, approved the appointment of Dr. Neeti Madan Kapre (DIN: 06801264) as an Additional Non-Executive Independent Director of the Company for a first term of five (5) consecutive years with effect from 11th July, 2026 till 10th July 2031.

The Board is of the opinion that Dr. Neeti Madan Kapre fulfils the conditions specified under the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for appointment as an Independent Director and is independent of the management of the Company and is not disqualified from holding the office of Director pursuant to the provision of Section 164 of the Companies act 2013.

Further, in accordance with the circulars issued by the Securities and Exchange Board of India, it is hereby confirmed that Dr. Neeti Madan Kapre is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority.

The disclosures required pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed as **Annexure – A**.

3. REDESIGNATION OF SHRI BALRAM VISWANATHAN (DIN: 10245195) FROM CHAIRMAN AND NON-EXECUTIVE INDEPENDENT DIRECTOR TO CHAIRMAN AND MANAGING DIRECTOR OF THE COMPANY.

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, approved the redesignation of Shri Balram Viswanathan (DIN: 10245195) from Chairman and Non-Executive Independent Director to Chairman and Managing Director of the Company and Key Managerial Personnel as per Companies Act 2013 and SEBI(LODR) Regulation, for a term of three (3) years commencing from 11th July, 2026 up to 10th July, 2029, subject to the approval of the Members of the Company at the ensuing General Meeting and such other statutory/regulatory approvals as may be required.

The terms and conditions of his appointment, including remuneration, shall be as approved by the Board and shall be subject to the approval of the Members of the Company.

Pursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, the requisite details relating to the redesignation of Shri Balram Viswanathan are enclosed as **Annexure – B**.

4. RECONSTITUTION OF THE COMMITTEES OF THE BOARD

pursuant to the demise of Shri Umesh Sandu (DIN:01132141) Managing Director and redesignation of Shri Balram Viswanathan (DIN: 10245195) as Chairman and Managing Director of the Company, the Board of Directors approved the reconstitution of the following Committees of the Board with immediate effect, in compliance with the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

- 1) Audit Committee;**
- 2) Nomination and Remuneration Committee; and**
- 3) Stakeholders' Relationship Committee.**

The revised composition of the aforesaid Committees is enclosed as **Annexure – C** to this Outcome of the Board Meeting.

5. REVISION OF VIGIL MECHANISM POLICY/WHISTLE BLOWER POLICY:



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

The Board of Directors approved the revision of the Company's Vigil Mechanism Policy by replacing the name of Late Shri Umesh B. Sandu with Shri Balram Viswanathan in his capacity as the Chairman and Managing Director, wherever applicable in the Policy. The revised Vigil Mechanism Policy shall be effective from the date of approval by the Board.

For Sandu Pharmaceuticals Limited



Pratika Mhambray
Company Secretary
ACS :36512



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in



ANNEXURE A

Disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sr No	Particulars	Details
1	Name of the Director/ Key Managerial Personnel	Dr Neeti Madan Kapre (DIN:06801264)
2	Reason for change	Appointment as Additional Non-Executive Independent Director
3	Date of appointment / Cessation & term of appointment	With effect from 11 th July 2026 <u>Term of appointment:</u> - Appointment of Dr Neeti Madan Kapre (DIN:06801264) as Non-Executive Independent Director for a term of five (5) years effective 11 th July 2026, subject to the approval of the shareholders of the Company, as per the regulatory requirements ,not liable to retire by rotation.
4	Brief Profile	Dr Neeti Madan Kapre has done <ul style="list-style-type: none"> • MBBS- Gold Medallist (First class with Distinction all 4 years)- Indira Gandhi Government Medical College, Nagpur • M.S (ENT) – K.E.M. Hospital, Mumbai • D.N.B (ENT) • Clinical Research Fellow, Head and Neck Services, TMH, Mumbai (August 2013 to August 2015) • Global Fellowship Programme, International Foundation Head and Neck Oncologic Societies • Observer ship under the Global Fellowship Programme at Memorial Sloan Kettering Cancer Centre, New York Memberships <ul style="list-style-type: none"> • Founder Member – <ul style="list-style-type: none"> (a) Indian Society of Thyroid Surgeons (b) Vidarbha Society of Head and Neck Oncology • Executive committee member- Indian Society of Thyroid Surgeons Thyroid Society Nagpur • Life Member <ul style="list-style-type: none"> - Asia Pacific Thyroid Society - Foundation of Head & Neck Oncology - Association of Otolaryngologist in India - Vidarbha Society of Head & Neck Oncology - Indian Society of Otolaryngologist.

5	Disclosure of relationships between directors (in case of appointment of a director)	Dr Neeti Madan Kapre is not related to any Director and/or Key Managerial Personnel and/or Promoters of the Company.
6	Information as required Circular No. LIST/COMP/14/2018- 19 and NSE/CML/2018/24	Dr Neeti Madan Kapre Not debarred from holding the office of a director by virtue of any order passed by SEBI

ANNEXURE B

Disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sr No	Particulars	Details
1	Name of the Director/ Key Managerial Personnel	Shri Balram Viswanathan (DIN: 10245195)
2	Reason for change	Redesignation from Chairman and Non-Executive Independent Director to Chairman and Managing Director
3	Date of appointment /Cessation & term of appointment	With effect from 11 th July 2026 Term of appointment: Shri Balram Viswanathan (DIN: 10245195) is appointed as Chairman and Managing Director for the term of 03 years with effect from 11 th July 2026 subject to the approval of the shareholders of the Company, as per the regulatory requirements
4	Brief Profile	Shri. Balram Viswanathan is a B.Com., FCA and CPA (USA) with over 30 years of rich and diverse experience in the financial services industry. An Ex-Banker, his areas of expertise include Audit, Taxation, Mergers & Acquisitions Advisory, Due Diligence, Compliance, Valuation Services, Financial Control, Financial Planning & Analysis, Regulatory Reporting, Business Strategy, Treasury and Risk Management.
5	Disclosure of relationships between directors (in case of appointment of a director)	Shri. Balram Viswanathan is not related to any Director and/or Key Managerial Personnel and/or Promoters of the Company.
6	Information as required Circular No. LIST/COMP/14/2018- 19 and NSE/CML/2018/24	Shri. Balram Viswanathan Not debarred from holding the office of a director by virtue of any order passed by SEBI

ANNEXURE C

Disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

A) Audit Committee

Sr No	Name	Category	Position
1	VIJAY KOTTAPALLI	Non Executive -Independent Director	Chairman
2	AJIT RAJARAM KANTAK	Non Executive -Independent Director	Member
3	BALRAM VISWANATHAN	Non Executive -Independent Director	Member

B) Nomination and Remuneration Committee

Sr No	Name	Category	Position
1	AJIT RAJARAM KANTAK	Non-Executive - Independent	Chairman
2	SHASHANK SANDU	Non-Executive - Non Independent Director	Member
3	VIJAY KOTTAPALLI	Non Executive -Independent Director	Member

C) Stakeholders Relationship Committee

Sr No	Name	Category	Position
1	SHASHANK SANDU	Non-Executive - Non Independent Director	Chairman
2	AJIT RAJARAM KANTAK	Non-Executive - Independent Director	Member
3	NEETI MADAN KAPRE	Non Executive Independent Director	Member

FOR SANDU PHARMACEUTICALS LIMITED.



Pratika Mhambray
Company Secretary
ACS : 36512



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

VIGIL MECHANISM / WHISTLE BLOWER POLICY

1. As per Section 177(9) of the Companies Act 2013 every Listed Company shall establish a Vigil Mechanism for Directors and Employees to report genuine concerns in such manner as per Rule 7 of the companies (Meetings of Board and its Powers) Rules 2014. Listing Obligation and Disclosure Requirement Regulation 2015 also requires a Vigil Mechanism for Directors and Employees to report concerns about unethical behaviour, actual or suspected fraud or violation of the company's code of conduct or ethics policy.

The Vigil Mechanism shall provide for adequate safeguards against victimization of persons who use such mechanism and make provision for direct access to the Chairperson of the Audit Committee in appropriate or exceptional case.

2. **Scope of the Policy:**

The policy covers malpractices and events which have taken place / suspected to have taken place, misuse or abuse of authority, fraud or suspected fraud, violation of company rules, manipulations, negligence causing danger to public health and safety, misappropriation of monies and other matters or activity on account of which the interest of the company is affected and formally reported by whistle blowers concerning its employees.

“**Whistle blower**” is an employee or group of employees who make a protected Disclosure under this policy and also referred as complainant.

“**Subject**” means a person or group of persons against or in relation to whom a protected Disclosure is made or evidence gathered during the course of an investigation.

“**Protected Disclosure**” means a concern caused by an employee or group of employees of the company, through a written communication and made in good faith which discloses or demonstrates information about an unethical or improper activity within the scope of the policy with respect to the company. The protected Disclosures should be factual and not speculative or in the nature of an interpretation / conclusion and should contain as much specific information as possible to allow for proper assessment of the nature and extent of the concern.

‘**Employee**’ means all the present employees and Chairman and Managing Director/ Whole Time Director of the company.

‘**Nodal Officer**’ means an officer of the company nominated by the Chairman and Managing Director / Whole Time Director to receive protected Disclosures from Whistle blower, maintaining records thereof, placing the same before the ‘Audit Committee’ for its disposal and informing the Whistle blower the result thereof.

‘**Audit Committee**’ means a committee constituted by the Board of Directors of the Company.

3. **Receipt and Disposal of Protected Disclosures**

- Protected Disclosures should be reported in writing by the complainant as soon as possible after the whistle blower becomes aware of the same so as to ensure a clear understanding of the issues raised and should either be typed or written in a legible handwriting in English or in Konkani



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

- The Protected Disclosure should be submitted in a closed and secured envelope and should be super scribed as "Protected Disclosure under the Whistle Blower Policy". If the complaint is not super scribed and closed as mentioned above it will not be possible for the Audit Committee to protect the complainant and the protected disclosure will be dealt with as if a normal disclosure. In order to protect identity of the complainant, the nodal officer will not issue any acknowledgement to the complainant and the complainants are advised neither to write the name / address of the complainant on the envelope nor to enter into any further correspondence with the nodal officer / audit committee. The audit committee assures that in case any further clarification is required he will get in touch with the complainant.
- Anonymous / pseudonymous disclosure shall not be entertained by the Nodal Officer.
- The Protected Disclosure should be forwarded under a covering letter signed by the complainant. The Nodal officer / MD / CFO / Chairman of Audit Committee shall detach the covering letter bearing the identity of the whistle blower and process only the Protected Disclosure.
- All protected Disclosures should be addressed to the Nodal Officer of the Company. The contact details of the Nodal officer is as under:-

Address of Nodal Officer -

Mr Balram Viswanathan
Sandu Pharmaceuticals Limited
Plot No 25,26,29 & 30,Pilerna Industrial Estate,Marra,
Bardez, Goa 403511

- Protected Disclosures against the Nodal Officer should be addressed to the Chairman and Managing Director / Whole Time Director of the Company and the Protected Disclosure against the MD / WTD of the company should be addressed to the Chairman of the Audit Committee. The Contact details of the CMD / WTD / and the Chairman of the Audit Committee are as under:

Name of MD	Mr Balram Viswanathan
Name of CFO	Mr Vijay Kajarekar
Name of the Chairman of the Audit Committee	Mr Vijay Kottapalli
Name of the Nodal Officer	Mr Balram Viswanathan
Address for communication	Sandu Pharmaceuticals Limited Plot No 25, 26, 29 & 30, Pilerna Industrial Estate,Marra , Bardez Goa 403511

- On receipt of the Protected Disclosure, the Nodal Officer / MD / CFO / Chairman of the Audit Committee shall make a record of the Protected Disclosure and also ascertain from the complainant whether he was the person who made the protected disclosure or not before referring the matter to the Audit Committee of **The Sandu Pharmaceuticals Limited** for further appropriate investigation and needful action. The record will include:
 - a) Brief facts;
 - b) Whether the same Protected Disclosure was raised previously by anyone, and if so, the outcome thereof;



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

- c) Whether the same Protected Disclosure was raised previously on the same subject;
- d) Details of actions taken by Nodal Officer / MD / CFO for processing the complaint.
- e) Findings of the Audit Committee;
- f) The recommendations of the Audit Committee / other action(s).

- The Audit Committee if deems fit may call for further information or particulars from the complainant.

4. Investigation

4.1 All protected disclosures under this policy will be recorded and thoroughly investigated. The Audit Committee (AC) may investigate and may at its discretion consider involving any other Officer of the Company including Vigilance and Security Officer of the Company for the purpose of investigation.

- The decision to conduct an investigation taken by the AC is by itself not an accusation and is to be treated as a neutral fact finding process.
- Subject(s) will normally be informed in writing of the allegations at the outset of a formal investigation and have opportunities for providing their inputs during the investigation.
- Subject(s) shall have a duty to co-operate with the AC or any of the Officers appointed by it in this regard to the extent that such cooperation will not compromise self incrimination protections available under the applicable laws.
- Subject(s) have a responsibility not to interfere with the investigation. Evidence shall not be withheld, destroyed or tampered with and witness shall not be influenced, coached, threatened or intimidated by the subject(s).
- Unless there are compelling reasons not to do so, subject(s) will be given the opportunity to respond to material findings contained in the investigation report. No allegation of wrong doing against a subject(s) shall be considered as maintainable unless there is good evidence in support of the allegation.
- Subject(s) have a right to be informed of the outcome of the investigations.
- The investigation shall be completed normally within 90 days of the receipt of the protected disclosure and is extendable by such period as the AC deems fit and as applicable.

5. Decision and Reporting

5.1 Audit Committee along with its recommendations will report its findings to the MD / CFO through the Nodal Officer within 15 days of receipt of report for further action as deemed fit. In case prima facie case exists against the subject, then the MD / CFO shall forward the said report with its recommendation to the concerned disciplinary authority for further appropriate action in this regard or shall close the matter, for which he shall record the reasons. Copy of above decision shall be addressed to the Audit Committee, the Nodal Officer, the complainant and the subject.

- In case the subject is a Nodal Officer of the Company, the protected disclosure shall be addressed to the MD / CFO who, after examining the protected disclosure shall forward the matter to the Audit Committee. The Audit Committee after providing an opportunity to the subject to explain his position and after complete of investigation shall submit a report along with its recommendation to the MD /



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

CFO After considering the report and recommendation as aforesaid, MD / CFO shall forward the said report with its recommendation to the concerned disciplinary authority for further appropriate action in this regard or shall close the matter, for which he shall record the reasons. Copy of the above decision shall be addressed to the Audit Committee, the Nodal Officer, the Complainant and the subject.

- In case the Subject is the MD / CFO of the Company, the Chairman of the Audit Committee after examining the Protected Disclosure shall forward the Protected Disclosure to other members of the Audit Committee if deemed fit. The Audit Committee shall appropriately and expeditiously investigate the Protected Disclosure.
- If the report of investigation is not to the satisfaction of the complainant, the complainant has the right to report the event to the appropriate legal or investigating agency.
- A complainant who makes false allegations of unethical & improper practices or about wrongful conduct of the subject to the Nodal Officer or the Audit Committee shall be subject to appropriate disciplinary action in accordance with the rules, procedures and policies of the Company.
- **Secrecy / Confidentiality**
- The complainant, Nodal Officer, Members of Audit Committee, the Subject and everybody involved in the process shall:
 1. Maintain confidentiality of all matters under this Policy.
 2. Discuss only to the extent or with those persons as required under this policy for completing the process of investigations.
 3. Not keep the papers unattended anywhere at any time.
 4. Keep the electronic mails / files under password.

➤ **Protection**

No unfair treatment will be meted out to a whistle blower by virtue of his / her having reported a Protected Disclosure under this policy. The Company, as a policy, condemns any kind of discrimination, harassment, victimization or any other unfair employment practice being adopted against Whistle Blowers. Complete protection will, therefore, be given to Whistle Blowers against any unfair practice like realization, threat or intimidation of termination / suspension of service, disciplinary action, transfer, demotion, refusal of promotion or the like including any direct or indirect use of authority to obstruct the Whistle Blower's right to continue to perform his duties / functions including making further Protected Disclosure. The Company will take steps to minimize difficulties, which the Whistle Blower may experience as a result of making the Protected Disclosure. Thus if the Whistle Blower is required to give evidence in criminal or disciplinary proceedings, the Company will arrange for the Whistle Blower to receive advice about the procedure etc.

A Whistle Blower may report any violation of the above clause to the Chairman of the Audit Committee, who shall investigate into the same and recommend suitable action to the management.

The identity of the Whistle Blower shall be kept confidential to the extent possible and permitted under law. The identity of the complainant will not be revealed unless he himself has made either his details public or disclosed his identity to any other office or authority. In the event of the identity of the complainant being disclosed, the audit committee is authorized to initiate appropriate action as per extant regulations against the person or agency making such disclosure. The identity of the Whistleblower, if known, shall remain confidential to those persons directly involved in applying this policy, unless the issue requires investigation by law enforcement agencies, in which case members of the organization are subject to subpoena.

Any other Employee assisting in the said investigation shall also be protected to the same extent as the



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in



ISO 9001:2015 CERTIFIED ORGANISATION



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Whistle Blower.

Provided however that the complainant before making a complaint has reasonable belief that an issue exists and he has acted in good faith. Any complaint not made in good faith as assessed as such by the Audit Committee shall be viewed seriously and the complainant shall be subject to disciplinary action as per the certified standing orders of the Company. This policy does not protect an employee from an adverse action taken independent of his disclosure of unethical and improper practice etc. unrelated to a disclosure made pursuant to this policy.

8. Access to Chairman of the Audit Committee

The Whistle Blower shall have right to access Chairman of the Audit Committee directly in exceptional cases and the Chairman of the Audit Committee is authorized to prescribe suitable directions in this regard.

9. Communication

A whistleblower policy cannot be effective unless it is properly communicated to employees. Employees shall be informed through by publishing in notice board and the web site of the Company.

10. Retention of Documents

All Protected Disclosures documented along with the results of Investigation relating thereto, shall be retained by the Nodal Officer for a period of 5 (five) years or such other period as specified by any other law in force, whichever is more.

11. Administration and Review of the Policy

The Chairman and Managing Director / Whole Time Director shall be responsible for the administration, interpretation, application and review of this policy. The Chairman and Managing Director / Whole Time Director also shall be empowered to bring about necessary changes to this Policy, if required at any stage with the concurrence of the Audit Committee.

12. Annual Affirmation

The Company shall annually affirm that it has provided protection to the complainant from unfair adverse personal action. The affirmation shall also form part of Corporate Governance report which is attached to the Annual report of the Company.

Updated at Board Meeting on 11th July 2027



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in

